An Open-label,Single-arm Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Icaritin (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Shenogen Pharma
- 07 Jun 2017 Biomarkers information updated
- 27 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 27 Jan 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.